Literature DB >> 3258863

Enoxacin in the treatment of lower respiratory tract infections.

F Philip-Joet1, J Nourrit, Y Frances, A Arnaud.   

Abstract

Twenty patients admitted to hospital with serious lower respiratory tract infections entered an open study of 400 mg enoxacin given orally twice a day for a minimum of seven days. Clinical signs and symptoms were completely cured or improved in six of eight patients with pneumonia, in nine of ten patients with bronchitis, and in two patients with bronchiectasis. Enoxacin was effective in eradicating the initial pathogens in 10 of 12 patients with positive cultures. Enoxacin was well tolerated. Only one treatment-related side-effect was observed during the study. Nine patients received concurrent treatment with theophylline, but no signs of theophylline toxicity were seen. Enoxacin is a safe and effective alternative to parenteral treatment of lower respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258863     DOI: 10.1093/jac/21.suppl_b.125

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 2.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G Gooch; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

Review 4.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 5.  Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.

Authors:  M J Wood
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 6.  Clinical overview of enoxacin.

Authors:  S H Zinner
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.